Notably, the depletion of NK cells in BCG-treated mice resulted in a reduction of the frequency of gp33-specific CD8+ T cells in the lungs (Fig. 6b) and diminished in vitro B16-F10-specific cytotoxicity compared to non-depleted mice (Fig. 6c), indicating the key role of NK cells in generating tumor-specific responses driven by IV BCG. Here, CD8A is linked to neoplasm.